Bayer says its experimental blood thinner cuts risk of stroke recurrence by 26%

Core Insights - Bayer's experimental blood thinner has demonstrated a 26% reduction in the risk of stroke recurrence during a late-stage trial, providing a significant boost to the company's turnaround efforts led by CEO Bill Anderson [1] Company Summary - The positive results from the trial represent a critical advancement for Bayer in the pharmaceutical sector, particularly in the development of treatments for stroke prevention [1]